ArticleBMC infectious diseases2026
UNAIDS 95-95-95 targets in older people living with HIV in urban and rural KwaZulu-Natal, South Africa.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundData describing HIV prevalence, ART use and virological suppression, in older adults in urban or rural South Africa, are limited. We aimed to address this evidence gap.
methodsIn a population-based cross-sectional study, using age- and sex-stratified random sampling of adults aged ≥ 40 years, a researcher-administered questionnaire collected socio-demographic, and clinical data (03/2022-04/2024). HIV was confirmed using two point-of-care tests (discrepancies resolved by ELISA). The age- and sex-specific study prevalence was applied to the KwaZulu Natal (KZN) province population structure to provide an illustrative projection of HIV prevalence in KZN. Achievement of UNAIDS 95-95-95 targets was calculated in 10-year age bands. People living with HIV (PLHIV) were categorised as virologically suppressed (< 50copies/mL) vs. unsuppressed, and younger (40-49years) vs. older (≥ 50years). Logistic regression determined associations with HIV and virological suppression.
results1,916 adults were recruited; 713 (37.2%) living with HIV, 36.7% men and 37.7% women. HIV prevalence was 68.1% among 40-49-year-olds, 49.4% among 50-59-year-olds, 26.0% among 60-69-year-olds and 9.8% age ≥ 70 years. In older adults (≥ 50 years), the prevalence was 27.9%. The overall projected standardised HIV prevalence in adults ≥ 40 years in KZN was 47.4% (44.8% men; 49.3% women). In our sample, 98% of PLHIV were aware of their status, 97.6% on ART, and 77.7% virologically suppressed. Men ≥ 70 years achieved highest virological suppression (88.2%). Overall, being female vs. male (57.8% vs. 42.2%; OR 1.6 [95%CI 1.1, 2.4]; p = 0.008), having HIV ≥ 3 years vs. < 3 years (62.2% vs. 55.1%; OR 3.0 [95%CI 1.6, 5.7]; p = 0.001), rural vs. urban living (50.9% vs. 49.1%; OR 1.5 [95%CI 1.0, 2.1]; p = 0.044) were associated with virological suppression. Older PLHIV (≥ 50years) vs. younger (40-49years) reported hypertension (51.0% vs. 30.0%), diabetes (10.0% vs. 5.0%), and polypharmacy (≥ 5 drugs) (13.2% vs. 6.3%).
conclusionIn KZN, the overall study prevalence of HIV in adults age ≥ 50 years was 27.9% in both urban and rural populations, the UNAIDS 95-95-95 targets were met for known status and being on treatment, but not virological suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.